Management of Advanced Ovarian Cancer: Current Clinical Practice and Future Perspectives.

Biomedicines · 2025 · PMC12292162 · PMID 40722601

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Final analysis showed a trend in favor of overall survival in favor of olaparib (51.7 vs. 38.8 months, HR = 0.74), but without statistical significance, probably due to the extended administration of PARP inhibitors in the placebo group after disease progression [ 55 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.